Angion Biomedica Corp Stock price
Is Angion Biomedica Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.
Key metrics
Angion Biomedica Corp Stock Analysis
Analyst Opinions
10 Analysts have issued a Angion Biomedica Corp forecast:
Analyst Opinions
10 Analysts have issued a Angion Biomedica Corp forecast:
Don't miss a Thing! We will send you all news about Angion Biomedica Corp directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Angion Biomedica Corp Stock News
Company Profile
Angion Biomedica Corp. operates as a biopharmaceutical company. It focuses on the discovery and development of novel therapeutic agents to address acute organ injuries and fibrotic diseases. Its product pipeline includes ANG-3777, ANG-3070, ROCK2 Inhibitor and CYP11B2 Inhibitors. The company was founded by Itzhak D. Goldberg on April 06, 1998 and is headquartered in Uniondale, NY.
| Head office | United States |
| CEO | Mr. Connelly |
| Employees | 33 |
| Founded | 2011 |
| Website | elicio.com |


